AstraZeneca is recalling one lot of professional/physician sample bottles of the blood thinner Brilinta because it may contain a different medication, according to a Food and Drug Administration (FDA) Safety Communication. The recall comes after AstraZeneca received a report that one of its sample bottles of eight Brilinta 90 milligrams (mg) tablets actually contained another AstraZeneca-manufactured medication, Zurampic 200 mg. “Unintentional dosing with Zurampic has the potential to lead to adverse renal effects including acute renal failure, which is more common when Zurampic is given alone as it should be used in combination with a xanthine oxidase inhibitor,” the FDA ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.